SCHEMBL5130143

SCHEMBL5130143

Cc1csc2nc(-n3ccnc3C)nc(NCc3ccc4c(c3)OCCO4)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 2/20 0.42
ESR1 P03372 1/20 0.41
ALDH1A1 P00352 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 2/20 0.41
TP53 P04637 1/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PDE5A O76074 2/20 0.38
CLK4 Q9HAZ1 4/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
PDE2A O00408 1/20 0.36
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5115267 0.95 ALDH1A1 (0.44) ESR1ALDH1A1NPSR1MAPTMEN1
SCHEMBL5122226 0.86 BCDIN3D (0.39) ESR1ALDH1A1NPSR1MAPTMEN1
SCHEMBL5114161 0.86 ALDH1A1 (0.47) CHRM4ALDH1A1NPSR1MAPTMEN1
SCHEMBL5118406 0.85 ESR1 (0.48) ESR1CLK4CLK1CLK2DYRK1A
SCHEMBL5128127 0.85 NOS2 (0.49) CHRM4ESR1ALDH1A1NPSR1MAPT
SCHEMBL5781706 0.84 HTT (0.48) CHRM4ALDH1A1NPSR1MAPTMEN1
SCHEMBL5119537 0.84 CHRM4 (0.42) CHRM4ALDH1A1NPSR1MAPTMEN1
SCHEMBL5128242 0.84 ALDH1A1 (0.42) CHRM4ESR1ALDH1A1NPSR1MAPT
SCHEMBL5116294 0.83 CHRM4 (0.42) CHRM4ALDH1A1NPSR1MAPTMEN1
SCHEMBL5118442 0.82 ESR1 (0.48) CHRM4ESR1ALDH1A1NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 CHRM4 4573/4885ESR1 2256/4885ALDH1A1 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.